• 1
    US Department of Health and Human Services. The Belmont Report. Accessed March 7, 2013.
  • 2
    Life Sciences World Inc. Phase 3 Clinical Trial Costs Exceed $26,000 per Patient. Accessed March 7, 2013.
  • 3
    Silverman E. Pharmalot: Clinical Trials Costs Are Rising Rapidly. pharmalotcom/2011/07/clinical-trial-costs-for-each-patient-rose-rapidly/. Access date.
  • 4
    Patlak M, Nass S, Rapporteurs. Improving the Quality of Cancer Clinical Trials: Workshop Summary. Washington, DC: National Academies Press; 2008.
  • 5
    Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010;28:2925-2935.
  • 6
    Berry SR, Neumann PJ, Bell C, et al. What price for a year of life? A survey of US and Canadian oncologists [abstract]. J Clin Oncol. 2009;27:339s. Abstract 6565.
  • 7
    Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109-2117.
  • 8
    Vickers AJ. Do we want more cancer patients on clinical trials if so, what are the barriers to greater accrual. Trials. 2008;9:31.
  • 9
    Cheng SK, Dietrich MS, Finnigan S, et al. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies [abstract]. J Clin Oncol. 2009;27:325s. Abstract CRA6509.
  • 10
    Dilts DM, Sandler AB, Cheng SK, et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol. 2009;27:1761-1766.
  • 11
    Schechter AN. The crisis in clinical research: endangering the half-century National Institutes of Health Consensus. JAMA. 1998;280:1440-1442.
  • 12
    Bardach E, Kagan RA. Going by the Book: The Problem of Regulatory Unreasonableness. 2nd ed. New Brunswick, NJ: Transaction Books; 2002.
  • 13
    Wikipedia. Contract Research Organizations. Accessed March 7, 2013.
  • 14
    Bauchner H, Fontanarosa P. Restoring confidence in the pharmaceutical industry. JAMA. 2013;309:607-609.